KPIs & Operating Metrics(New)
Growth Metrics

Charles River Laboratories International (CRL) Long-Term Deferred Tax (2016 - 2025)

Charles River Laboratories International has reported Long-Term Deferred Tax over the past 16 years, most recently at $67.3 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax rose 59.64% year-over-year to $67.3 million; the TTM value through Dec 2025 reached $67.3 million, up 59.64%, while the annual FY2025 figure was $67.3 million, 59.64% up from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $67.3 million at Charles River Laboratories International, up from $36.9 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $67.3 million in Q4 2025 and troughed at $31.9 million in Q2 2021.
  • A 5-year average of $41.1 million and a median of $40.3 million in 2021 define the central range for Long-Term Deferred Tax.
  • Biggest five-year swings in Long-Term Deferred Tax: decreased 25.48% in 2021 and later skyrocketed 59.64% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $40.2 million in 2021, then grew by 2.58% to $41.3 million in 2022, then dropped by 2.38% to $40.3 million in 2023, then grew by 4.72% to $42.2 million in 2024, then skyrocketed by 59.64% to $67.3 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for CRL at $67.3 million in Q4 2025, $36.9 million in Q3 2025, and $46.9 million in Q2 2025.